Skip to main content
Top
Published in: Clinical Oral Investigations 8/2013

01-11-2013 | Original Article

Dental risk factors for osteonecrosis of the jaws: a CONDOR case–control study

Authors: A. Barasch, J. Cunha-Cruz, F. Curro, T. DeRouen, G. H. Gilbert, P. Hujoel, M. M. Safford, D. A. Vena, A. E. Voinea-Griffin, H. Wu, for the CONDOR Collaborative Group

Published in: Clinical Oral Investigations | Issue 8/2013

Login to get access

Abstract

Background

Reports of osteonecrosis of the jaw (ONJ) have associated this lesion to treatment with bisphosphonates (BPs) and dental procedures. In this study, we investigated the association of specific dental diagnoses and procedures with ONJ among patients with past BP use.

Methods

Dentists from three practice-based research networks provided ONJ cases and controls (1:3). Data gathered from patients and dental offices with two respective standard questionnaires included demographic, medical, pharmaceutical, and dental information. Diagnoses and procedures up to 3 years prior to ONJ (prior to interview for controls) were analyzed within risk strata, defined by BP use and cancer status, using interaction terms within conditional logistic regression models.

Results

We enrolled 191 ONJ cases and 573 controls from 119 dental offices. Among participants who had used only oral BP, extraction was the only dental risk factor for ONJ (odds ratio (OR) = 12, p = 0.01). Suppuration was also more prevalent in cases (18 %) than in controls (9 %), but not statistically significant (OR = 9, p = 0.06). Among participants who had not used either oral or IV BP (a majority of whom received radiation therapy to the head and neck), suppuration was the only dental risk factor for ONJ (prevalence = 34 % for cases and 8 % for controls; OR = 7, p = 0.01). The prevalence of extractions in this group was also higher, but not statistically significant (44 vs 10 %; OR = 3). Limited power precludes definitive findings among participants exposed to IV BP.

Conclusions

Among patients taking oral BP, extraction was the only dental procedure associated with subsequent ONJ development

Clinical relevance

Results of this study suggest that routine dental procedures are not associated with development of ONJ in patients exposed to BPs.
Literature
1.
go back to reference Merigo E, Manfredi M, Meleti M, Corradi D, Vescovi P (2005) Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report. J Oral Pathol Med 34:613–617PubMedCrossRef Merigo E, Manfredi M, Meleti M, Corradi D, Vescovi P (2005) Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report. J Oral Pathol Med 34:613–617PubMedCrossRef
2.
go back to reference Badros A, Weikel D, Salama A et al (2006) Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24:945–952PubMedCrossRef Badros A, Weikel D, Salama A et al (2006) Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24:945–952PubMedCrossRef
3.
go back to reference Bamias A, Kastritis E, Bamia C et al (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23:8580–8587PubMedCrossRef Bamias A, Kastritis E, Bamia C et al (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23:8580–8587PubMedCrossRef
4.
go back to reference Farrugia MC, Summerlin DJ, Krowiak E et al (2006) Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laryngoscope 116:115–120PubMedCrossRef Farrugia MC, Summerlin DJ, Krowiak E et al (2006) Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laryngoscope 116:115–120PubMedCrossRef
5.
go back to reference Migliorati CA (2003) Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol 21:4253–4254PubMedCrossRef Migliorati CA (2003) Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol 21:4253–4254PubMedCrossRef
6.
go back to reference Rosenberg T, Ruggiero S (2003) Osteonecrosis of the jaws associated with the use of bisphosphonates. Paper presented at: 85th Annual American Association of Oral and Maxillofacial Surgeons Meeting; September 10–13, 2003; Orlando, FL Rosenberg T, Ruggiero S (2003) Osteonecrosis of the jaws associated with the use of bisphosphonates. Paper presented at: 85th Annual American Association of Oral and Maxillofacial Surgeons Meeting; September 10–13, 2003; Orlando, FL
7.
go back to reference Wang J, Goodger NM, Pogrel MA (2003) Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 61:1104–1107PubMedCrossRef Wang J, Goodger NM, Pogrel MA (2003) Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 61:1104–1107PubMedCrossRef
8.
go back to reference Devogelaer JP (2000) Treatment of bone diseases with bisphosphonates, excluding osteoporosis. Curr Opin Rheumatol 12:331–335PubMedCrossRef Devogelaer JP (2000) Treatment of bone diseases with bisphosphonates, excluding osteoporosis. Curr Opin Rheumatol 12:331–335PubMedCrossRef
9.
go back to reference Fournier P, Boissier S, Filleur S et al (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62:6538–6544PubMed Fournier P, Boissier S, Filleur S et al (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62:6538–6544PubMed
10.
go back to reference Santini D, Vincenzi B, Galluzzo S et al (2007) Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 13:4482–4486PubMedCrossRef Santini D, Vincenzi B, Galluzzo S et al (2007) Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 13:4482–4486PubMedCrossRef
11.
go back to reference Assouline-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME (2002) Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum 32:94–124PubMed Assouline-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME (2002) Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum 32:94–124PubMed
12.
go back to reference Moreira MS, Katayama E, Bombana AC, Marques MM (2005) Cytotoxicity analysis of alendronate on cultured endothelial cells and subcutaneous tissue: a pilot study. Dent Traumatol 21:329–335PubMedCrossRef Moreira MS, Katayama E, Bombana AC, Marques MM (2005) Cytotoxicity analysis of alendronate on cultured endothelial cells and subcutaneous tissue: a pilot study. Dent Traumatol 21:329–335PubMedCrossRef
13.
go back to reference Hoefert S, Schmitz I, Tannapfel A, Eufinger H (2010) Importance of microcracks in etiology of bisphosphonates-realted osteonecrosis of the jaw: a possible pathogenic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. Clin Oral Investig 4:271–284CrossRef Hoefert S, Schmitz I, Tannapfel A, Eufinger H (2010) Importance of microcracks in etiology of bisphosphonates-realted osteonecrosis of the jaw: a possible pathogenic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. Clin Oral Investig 4:271–284CrossRef
14.
go back to reference Barasch A, Cunha-Cruz J, Curro FA et al (2011) Risk factors for osteonecrosis of the jaw: a case–control study from the CONDOR Dental PBRN. J Dent Res 90:439–444PubMedCrossRef Barasch A, Cunha-Cruz J, Curro FA et al (2011) Risk factors for osteonecrosis of the jaw: a case–control study from the CONDOR Dental PBRN. J Dent Res 90:439–444PubMedCrossRef
15.
go back to reference Woo SB, Hellstein JW, Kalmar JR (2006) Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753–761PubMedCrossRef Woo SB, Hellstein JW, Kalmar JR (2006) Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753–761PubMedCrossRef
16.
go back to reference Rustemeyer J, Bremerich A (2010) Bisphosphonate-associated osteonecrosis of the jaw: what do we currently know? A survey of knowledge given in the recent literature. Clin Oral Invest 14:59–64CrossRef Rustemeyer J, Bremerich A (2010) Bisphosphonate-associated osteonecrosis of the jaw: what do we currently know? A survey of knowledge given in the recent literature. Clin Oral Invest 14:59–64CrossRef
17.
go back to reference Hansen T, Kunkel M, Weber A, James Kirkpatrick C (2006) Osteonecrosis of the jaws in patients treated with bisphosphonates—histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 35:155–160PubMedCrossRef Hansen T, Kunkel M, Weber A, James Kirkpatrick C (2006) Osteonecrosis of the jaws in patients treated with bisphosphonates—histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 35:155–160PubMedCrossRef
18.
go back to reference D’Agostino RB Jr (1998) Propensity score methods for bias reduction for the comparison of a treatment to a non-randomized control group. Stat Med 17:2265–2281PubMedCrossRef D’Agostino RB Jr (1998) Propensity score methods for bias reduction for the comparison of a treatment to a non-randomized control group. Stat Med 17:2265–2281PubMedCrossRef
19.
go back to reference Rubin DB, Thomas N (2000) Combining propensity score matching with additional adjustments for prognostic covariates. J Am Stat Assoc 95:573–585CrossRef Rubin DB, Thomas N (2000) Combining propensity score matching with additional adjustments for prognostic covariates. J Am Stat Assoc 95:573–585CrossRef
20.
go back to reference Bagan JV, Murillo J, Jimenez Y et al (2005) Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 34:120–123PubMedCrossRef Bagan JV, Murillo J, Jimenez Y et al (2005) Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 34:120–123PubMedCrossRef
21.
go back to reference Solomon DH, Mercer E, Woo SB, Avorn J, Schneeweiss S, Treister N (2012) Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges. Osteoporos Int; Epub ahead of print Solomon DH, Mercer E, Woo SB, Avorn J, Schneeweiss S, Treister N (2012) Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges. Osteoporos Int; Epub ahead of print
22.
go back to reference Otto S, Abo-Id MH, Fedele S et al (2011) Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: not just a sporadic cincidence—a multi-centre study. J Craniomaxillofac Surg 39:272–277PubMedCrossRef Otto S, Abo-Id MH, Fedele S et al (2011) Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: not just a sporadic cincidence—a multi-centre study. J Craniomaxillofac Surg 39:272–277PubMedCrossRef
23.
go back to reference Richards D (2008) Guidelines for bisphosphonate-associated osteonecrosis of the jaw. Evid Based Dent 9:101–102PubMedCrossRef Richards D (2008) Guidelines for bisphosphonate-associated osteonecrosis of the jaw. Evid Based Dent 9:101–102PubMedCrossRef
24.
go back to reference Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B (2009) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws—2009 update. J Oral Maxillofac Surg 67(5 Suppl):2–12PubMed Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B (2009) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws—2009 update. J Oral Maxillofac Surg 67(5 Suppl):2–12PubMed
25.
go back to reference Eisbruch A, Harris J, Garden AS et al (2010) Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00–22). Int J Radiat Oncol Biol Phys 76:1333–1338PubMedCrossRef Eisbruch A, Harris J, Garden AS et al (2010) Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00–22). Int J Radiat Oncol Biol Phys 76:1333–1338PubMedCrossRef
Metadata
Title
Dental risk factors for osteonecrosis of the jaws: a CONDOR case–control study
Authors
A. Barasch
J. Cunha-Cruz
F. Curro
T. DeRouen
G. H. Gilbert
P. Hujoel
M. M. Safford
D. A. Vena
A. E. Voinea-Griffin
H. Wu
for the CONDOR Collaborative Group
Publication date
01-11-2013
Publisher
Springer Berlin Heidelberg
Published in
Clinical Oral Investigations / Issue 8/2013
Print ISSN: 1432-6981
Electronic ISSN: 1436-3771
DOI
https://doi.org/10.1007/s00784-012-0880-4

Other articles of this Issue 8/2013

Clinical Oral Investigations 8/2013 Go to the issue